| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/01/2006 | CA2579962A1 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| 05/31/2006 | EP1661993A1 SLY1 inhibitors in organ, tissue and cell transplantation |
| 05/31/2006 | EP1661990A1 Polypeptide specific to liver cancer, polynucleotide encoding the polypeptide and rna molecule inhibiting the expression of the polypeptide |
| 05/31/2006 | EP1661904A1 Novel azalide and azalactam derivatives and process for the production of the same |
| 05/31/2006 | EP1661898A1 Bicyclic piperazine compound and use thereof |
| 05/31/2006 | EP1661897A1 Pyrrolopyrimidinone derivative |
| 05/31/2006 | EP1661896A1 Pyrrolopyrimidinethione derivative |
| 05/31/2006 | EP1661895A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione,maleic acid salt,hydrate as pharmaceutical |
| 05/31/2006 | EP1661892A1 Condensed ring compound and use thereof |
| 05/31/2006 | EP1661890A1 Ppar-activating compound and pharmaceutical composition containing same |
| 05/31/2006 | EP1661883A1 13-substituted methacycline compounds |
| 05/31/2006 | EP1661882A1 Compound having anti-hcv activity and process for producing the same |
| 05/31/2006 | EP1661881A2 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 05/31/2006 | EP1661878A1 Adapalene polymorphic forms |
| 05/31/2006 | EP1661582A1 Cancer metastasis inhibitor |
| 05/31/2006 | EP1661581A1 Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
| 05/31/2006 | EP1661580A1 Remedy for cartilage-related diseases |
| 05/31/2006 | EP1661574A1 Beta-hydroxy short to medium chain fatty acid polymer |
| 05/31/2006 | EP1661573A1 Ophthalmic composition |
| 05/31/2006 | EP1661572A1 Novel use of cannabinoid receptor agonist |
| 05/31/2006 | EP1661571A2 Medicaments for preventing intervention-associated stenosis following non-bypass, invasive interventions |
| 05/31/2006 | EP1661570A2 Compositions comprising ipatropium and xylometazoline for treatment of the common cold |
| 05/31/2006 | EP1661569A1 Compounds effecting glucokinase |
| 05/31/2006 | EP1661568A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661567A1 Compounds effecting Glucokinase |
| 05/31/2006 | EP1661566A2 Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| 05/31/2006 | EP1661565A1 Composition for the treatment of vitiligo |
| 05/31/2006 | EP1661564A1 Heterocyclic compounds and their pharmaceutical use |
| 05/31/2006 | EP1661563A1 Compound effecting Glucokinase |
| 05/31/2006 | EP1661562A1 Sphingolipids in treatment and prevention of steatosis |
| 05/31/2006 | EP1661561A1 Cosmetic and dermatological compositions for the treatment of the skin and scalp |
| 05/31/2006 | EP1660687A2 Rnai-based modification of heterochromatin |
| 05/31/2006 | EP1660685A2 Antisense inhibition of laminin-8 expression to inhibit human gliomas |
| 05/31/2006 | EP1660630A2 Nucleic acid biomaterials and methods of formation and use |
| 05/31/2006 | EP1660522A2 Pharmaceutical composition with increased bioavailability suitable for the administration of oral retroviral protease inhibitors. process for preparing a concentrate pharmaceutical composition comprising a retroviral protease inhibitor |
| 05/31/2006 | EP1660516A1 Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters |
| 05/31/2006 | EP1660506A2 Oral neurotherapeutic cefazolin compositions |
| 05/31/2006 | EP1660502A2 MODULATION OF ß-CATENIN/TCF ACTIVATED TRANSCRIPTION |
| 05/31/2006 | EP1660500A1 Substituted imidazopyrimidines for the prevention and treatment of cancer |
| 05/31/2006 | EP1660496A1 Process for the synthesis of zolpidem |
| 05/31/2006 | EP1660493A1 Peptidyl heterocyclic ketone derivatives and preparation processes |
| 05/31/2006 | EP1660490A1 Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 05/31/2006 | EP1660488A1 Novel antimicrobial aryloxazolidinone compounds |
| 05/31/2006 | EP1660487A1 Pyrrole compositions useful as inhibitors of c-met |
| 05/31/2006 | EP1660486A1 Halogenated quinazolinyl nitrofurans as antibacterial agents |
| 05/31/2006 | EP1660482A1 3- [(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] -methyl}-1-methyl-1h -benzimidazol-5-car bonyl)-pyridine-2-yl-amino -propionic acid ethyl ester metha ne sulphonate and use thereof as a medicament |
| 05/31/2006 | EP1660475A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 05/31/2006 | EP1660474A1 Substituted thiophenes and uses thereof |
| 05/31/2006 | EP1660467A2 Aminofurazan compounds as protein kinase inhibitors |
| 05/31/2006 | EP1660460A1 Quinoxaline derivatives as neutrophil elastase inhibitors and their use |
| 05/31/2006 | EP1660459A2 Arylsulfonamidobenzylic compounds |
| 05/31/2006 | EP1660456A2 Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones |
| 05/31/2006 | EP1660451A2 New crystalline forms of carvedilol |
| 05/31/2006 | EP1660444A2 Metal complexes of n-heterocyclic carbenes as radiopharmaceuticals and antibiotics |
| 05/31/2006 | EP1660443A2 Cyclic amine bace-1 inhibitors having a benzamide substituent |
| 05/31/2006 | EP1660440A2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| 05/31/2006 | EP1660434A1 Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition |
| 05/31/2006 | EP1660428A1 Ppar modulators |
| 05/31/2006 | EP1660427A1 Substituted arylalkanoic acid derivative and use thereof |
| 05/31/2006 | EP1660185A2 Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors |
| 05/31/2006 | EP1660184A2 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 05/31/2006 | EP1660183A2 Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4) |
| 05/31/2006 | EP1660137A2 Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors |
| 05/31/2006 | EP1660132A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor |
| 05/31/2006 | EP1660130A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression |
| 05/31/2006 | EP1660122A2 Immunostimulatory combinations and treatments |
| 05/31/2006 | EP1660116A1 Method of treating viral infections |
| 05/31/2006 | EP1660109A2 Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| 05/31/2006 | EP1660107A1 A ginseng preparation using vinegar and process for thereof |
| 05/31/2006 | EP1660103A2 Enhancement of magnesium uptake in mammals |
| 05/31/2006 | EP1660102A1 New therapeutic use of chondroitin sulphate |
| 05/31/2006 | EP1660101A1 Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| 05/31/2006 | EP1660100A1 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents |
| 05/31/2006 | EP1660099A1 Intravascular delivery of non-viral nucleic acid |
| 05/31/2006 | EP1660098A1 Use of surfactant preparations for the treatment of surgical adhesions |
| 05/31/2006 | EP1660097A1 Physiologically active composition based on phosphatidylserine |
| 05/31/2006 | EP1660096A1 Cyclohexyl prostaglandin analogs as ep-4 -receptor agonists |
| 05/31/2006 | EP1660095A2 Tricyclic parp inhibitors |
| 05/31/2006 | EP1660094A2 Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| 05/31/2006 | EP1660093A1 Ammonium salts of ornithine derivatives for treating inflammatory diseases |
| 05/31/2006 | EP1660092A2 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| 05/31/2006 | EP1660089A1 Chemokine inhibiting piperazine derivatives and their use to treat myocarditis |
| 05/31/2006 | EP1660088A2 Pyridomorphinans, pyridazinomorphinans and use thereof |
| 05/31/2006 | EP1660086A2 Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease |
| 05/31/2006 | EP1660085A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 05/31/2006 | EP1660084A2 Proton pump inhibitors for the treatment of lower abdominal disorders |
| 05/31/2006 | EP1660083A2 Stable pharmaceutical composition of rabeprazole |
| 05/31/2006 | EP1660082A1 Use of a compound in the treatment of sleep disorders |
| 05/31/2006 | EP1660080A1 Furanone derivatives |
| 05/31/2006 | EP1660079A2 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia |
| 05/31/2006 | EP1660078A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions. |
| 05/31/2006 | EP1660076A1 Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1 |
| 05/31/2006 | EP1660075A2 Protective and therapeutic uses for tocotrienols |
| 05/31/2006 | EP1660074A1 7-carboxymethyloxy-3 , 4 , 5-trimethoxy flavone monohyd rate, the preparation method and uses thereof |
| 05/31/2006 | EP1660073A2 Hydrophobic drug compositions containing reconstitution enhancer |
| 05/31/2006 | EP1660072A2 Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer |
| 05/31/2006 | EP1660071A1 Treatment of neurodegenerative conditions |
| 05/31/2006 | EP1660070A2 Selected betaines and their uses |
| 05/31/2006 | EP1660069A2 Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer's disease and retinal degeneration |
| 05/31/2006 | EP1660068A1 Composition for treatment of tinea pedis and method of use |